Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Zhiyue Rao, Jian Fang et al.|Nature Medicine|2025Cited by 30
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lü, Shucai Zhang, Hong Jian et al.|Journal of Thoracic Oncology|2022Cited by 25
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA studyShun Lü, Weiguo Su, Gongyan Chen et al.|Lung Cancer|2020Cited by 21
Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancerQian Miao, Zhijie Wang, Qian Chu et al.|Thoracic Cancer|2024Cited by 19
Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancerDingzhi Huang, Qian Miao, Qian Chu et al.|Thoracic Cancer|2023Cited by 5